Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 2/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.55 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5105487 | 0.97 | LMNA (0.57) | S1PR2S1PR1S1PR3LPAR2LMNA | |
| SCHEMBL5105170 | 0.85 | S1PR1 (0.56) | S1PR1S1PR3LMNAALDH1A1 | |
| SCHEMBL26499206 | 0.83 | S1PR2 (0.61) | S1PR2S1PR1S1PR3LPAR2LMNA | |
| SCHEMBL26497631 | 0.82 | S1PR2 (0.60) | S1PR2S1PR1S1PR3LPAR2SMN1; SMN2 | |
| SCHEMBL26497466 | 0.80 | S1PR2 (0.57) | S1PR2S1PR1S1PR3LPAR2LMNA | |
| SCHEMBL5099013 | 0.80 | GID4 (0.65) | — | |
| SCHEMBL25807952 | 0.79 | S1PR2 (0.62) | S1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL5096244 | 0.78 | S1PR2 (0.62) | S1PR2S1PR1S1PR3LPAR2LMNA | |
| SCHEMBL10052930 | 0.77 | S1PR2 (0.55) | S1PR2S1PR1S1PR3LPAR2SMN1; SMN2 | |
| SCHEMBL5092458 | 0.77 | S1PR2 (0.64) | S1PR2S1PR1S1PR3LPAR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7411091-B2 | N-acyl-N′-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2008-08-12 | — | — | US | claimed |
| EP-1689708-B1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARM SPA (IT) | 2007-06-27 | — | — | EP | claimed |
| US-20070142455-A1 | N-acyl-n'-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-21 | — | — | US | claimed |
| CN-1886370-A | N-acyl-N' -benzyl-alkylenediamino derivatives | NEWRON PHARM SPA (IT) | 2006-12-27 | — | — | CN | claimed |
| EP-1689708-A1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-16 | — | — | EP | claimed |
| WO-2005054189-A1 | N-ACYL-N'-BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | claimed |
| EP-1535908-A1 | N-acyl-N'-benzyl-alkylendiamino drivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-01 | — | — | EP | claimed |
| US-7411091-B2 | N-acyl-N′-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2008-08-12 | — | — | US | disclosed |
| EP-1689708-B1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARM SPA (IT) | 2007-06-27 | — | — | EP | disclosed |
| US-20070142455-A1 | N-acyl-n'-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| CN-1886370-A | N-acyl-N' -benzyl-alkylenediamino derivatives | NEWRON PHARM SPA (IT) | 2006-12-27 | — | — | CN | disclosed |
| EP-1689708-A1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054189-A1 | N-ACYL-N'-BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | disclosed |
| EP-1535908-A1 | N-acyl-N'-benzyl-alkylendiamino drivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142455-A1 | N-acyl-n'-benzyl-alkylendiamino derivatives | SCN7A, HTR7, TRPC7 | S1PR2 1796/4885S1PR1 1719/4885S1PR3 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.